Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig + Ezabenlimab in DLL3+ SCLC and Neuroendocrine Neoplasms
NCT05879978Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of obrixtamig in Small Cell Lung Cancer (SCLC) and Neuroendocrine neoplasm (NEN), sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicities in MTD evaluation period at 19 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
Small Cell Lung Cancer (SCLC)Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05879978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879978.